BioSpace News Archive

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices Inc.,

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company’s first quarter 2020 financial results

Today, Natalie Serratos from Oak Park & River Forest High School took first place at the Illinois BioGENEius Challenge, an annual student science and research competition hosted by the iBIO and sponsored by Horizon Therapeutics.

The Perrigo Company plc Board of Directors considers the well-being of shareholders, employees and service providers at the upcoming Annual General Meeting a primary concern and, in this context, has been closely monitoring developments in relation to the Coronavirus.

ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today reported its financial results for the first quarter ended March 31, 2020.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has applied for an Emergency Use Authorization (EUA) for the Lyra® Direct SARS-CoV-2 Assay from the Food and Drug Administration (FDA) to allow direct sample processing.

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2020. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards..

Samsung Biologics and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018.

The China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for two indications for avapritinib, a first-in-class precision therapy, in gastrointestinal stromal tumor (GIST), marking a key milestone in CStone’s transition toward commercialization